SEC Form 4 · accession 0001816523-26-000005
LENZ Therapeutics, Inc. · LENZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Zachary Scheiner
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 15, 2026 · 8:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $6.63 | Jun 15, 2026 | A | 22,100 | A | — | Jun 15, 2036 | Common Stock | 22,100 | 22,100 | D |
Explanation of responses
- F1Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
- F2Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.